Valuation Boston Scientific Corporation
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.32 USD | -1.44% |
|
-4.69% | -44.02% |
| 05-07 | Boston Scientific to Update Pacemakers in Recall, FDA Says | DJ |
| 05-07 | US FDA issues recall of Boston Scientific heart devices | RE |
Company Valuation: Boston Scientific Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 60,534 | 66,273 | 84,691 | 131,642 | 141,351 | 80,412 | - | - |
| Change | - | 9.48% | 27.79% | 55.44% | 7.37% | -43.11% | - | - |
| Enterprise Value (EV) 1 | 67,674 | 74,280 | 92,928 | 141,974 | 150,822 | 86,706 | 83,311 | 79,310 |
| Change | - | 9.76% | 25.1% | 52.78% | 6.23% | -42.51% | -3.92% | -4.8% |
| P/E ratio | 61.6x | 103x | 54x | 71.5x | 49.1x | 19.9x | 18.9x | 16.5x |
| PBR | 3.64x | 3.77x | 4.39x | 6.05x | 5.84x | 2.88x | 2.54x | 2.28x |
| PEG | - | -3x | 0x | 4.3x | 0.9x | 0.5x | 3.35x | 1.2x |
| Capitalization / Revenue | 5.09x | 5.23x | 5.95x | 7.86x | 7.04x | 3.71x | 3.4x | 3.13x |
| EV / Revenue | 5.69x | 5.86x | 6.53x | 8.48x | 7.51x | 4x | 3.53x | 3.09x |
| EV / EBITDA | 16.5x | 20.8x | 22.6x | 29.3x | 25.3x | 13x | 11.3x | 9.68x |
| EV / EBIT | 22.5x | 22.9x | 24.9x | 31.3x | 26.9x | 14.1x | 12.3x | 10.5x |
| EV / FCF | 51.4x | 79.2x | 51.9x | 53.7x | 41.2x | 20.7x | 19.8x | 14.9x |
| FCF Yield | 1.94% | 1.26% | 1.93% | 1.86% | 2.43% | 4.84% | 5.06% | 6.72% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.69 | 0.45 | 1.07 | 1.25 | 1.94 | 2.713 | 2.866 | 3.272 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 11,888 | 12,682 | 14,240 | 16,747 | 20,074 | 21,680 | 23,618 | 25,659 |
| EBITDA 1 | 4,103 | 3,574 | 4,106 | 4,839 | 5,973 | 6,681 | 7,391 | 8,196 |
| EBIT 1 | 3,010 | 3,241 | 3,738 | 4,529 | 5,612 | 6,170 | 6,799 | 7,533 |
| Net income 1 | 985 | 642 | 1,570 | 1,853 | 2,898 | 3,958 | 4,177 | 4,890 |
| Net Debt 1 | 7,140 | 8,007 | 8,237 | 10,332 | 9,471 | 6,294 | 2,899 | -1,102 |
| Reference price 2 | 42.48 | 46.27 | 57.81 | 89.32 | 95.35 | 54.10 | 54.10 | 54.10 |
| Nbr of stocks (in thousands) | 1,424,992 | 1,432,311 | 1,464,983 | 1,473,827 | 1,482,442 | 1,486,355 | - | - |
| Announcement Date | 02/02/22 | 01/02/23 | 31/01/24 | 05/02/25 | 04/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 19.94x | 4x | 12.98x | -.--% | 80.41B | ||
| 22.74x | 4.22x | 16.25x | 0.4% | 171B | ||
| 47.43x | 12.42x | 27.85x | -.--% | 153B | ||
| 26.36x | 4.97x | 15.5x | 0.89% | 118B | ||
| 28.29x | 6.28x | 19.98x | -.--% | 45.91B | ||
| 17.67x | 2.07x | 10.54x | 2.95% | 44.35B | ||
| 36.28x | 6.03x | 18.39x | -.--% | 34.57B | ||
| 21.65x | 4.44x | 15.39x | 0.9% | 31.91B | ||
| 23.27x | 5.04x | 15.7x | 2.7% | 29.63B | ||
| 19.23x | 5.07x | 12.94x | 1.19% | 29.56B | ||
| Average | 26.29x | 5.45x | 16.55x | 0.9% | 73.76B | |
| Weighted average by Cap. | 28.64x | 6.18x | 17.97x | 0.61% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- BSX Stock
- Valuation Boston Scientific Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















